Genprex Inc., a clinical-stage gene therapy company, has announced the presentation of positive preclinical research findings on its diabetes gene therapy drug candidate, GPX-002, at the 2025 American Diabetes Association 85th Scientific Sessions in Chicago. The research demonstrated that GPX-002 aids in the transdifferentiation of alpha cells into beta-like cells, leading to improved glucose homeostasis in animal models of Type 1 diabetes. The study, presented by Dr. Hannah Rinehardt, utilized recombinant adeno-associated virus (rAAV) to deliver the Pdx1 and MafA genes into the pancreatic duct, reversing diabetes without the need for immunosuppression in mouse models. Current preclinical studies are ongoing in non-human primate models to further evaluate the therapy's efficacy and immune response management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.